The Zacks Analyst Blog Highlights: Par Pharmaceutical Companies, Intellipharmaceutics International, Celgene Corporation, Novartis AG and Elan Corporation plc

Aug 22, 2011, 09:55 ET from Zacks Investment Research, Inc.

CHICAGO, Aug. 22, 2011 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Par Pharmaceutical Companies Inc. (NYSE: PRX), Intellipharmaceutics International Inc. (Nasdaq: IPCI) Celgene Corporation (Nasdaq: CELG) Novartis AG (NYSE: NVS) and Elan Corporation plc (NYSE: ELN).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday's Analyst Blog:

Par Pharma, IPCI Expand Deal

Par Pharmaceutical Companies Inc. (NYSE: PRX) and Intellipharmaceutics International Inc. (Nasdaq: IPCI) recently announced the expansion of their collaboration for the development and commercialization of additional strengths of their generic version of Focalin XR (dexmethylphenidate hydrochloride). The agreement covers only the US market.

The companies already have an agreement for the development and commercialization of 5, 10, 15 and 20 mg strengths of generic Focalin XR. According to the deal, Intellipharmaceutics is responsible for all development costs of generic Focalin XR, while Par Pharma is responsible for bioequivalence costs, API costs, scale-up/stability costs and marketing of the product. Par Pharma is also responsible for all litigation expenses.

Additionally, according to the expanded agreement, Par Pharma will make an upfront payment to Intellipharmaceutics and the latter is also entitled to receive a share of profits from the sales of the drug.

We note that Focalin XR, which is marketed for the treatment of attention-deficit hyperactivity disorder (ADHD), was licensed by Celgene Corporation (Nasdaq: CELG) to Novartis AG (NYSE: NVS). According to the agreement, Celgene granted Novartis the worldwide (excluding Canada) rights to develop and market Focalin XR. In return, Celgene received an upfront payment and is eligible to receive certain milestone payments.

The branded Focalin XR was approved by the US Food and Drug Administration (FDA) to be used as a treatment for ADHD in May 2005. In May 2007, Par Pharma and Intellipharmaceutics filed abbreviated new drug applications (ANDA) with the FDA seeking approval to market the generic versions of 5, 10, 15 and 20 mg doses of Focalin XR. Further, in December 2010, Intellipharmaceutics alone filed an ANDA with the FDA for the 30 mg strength of generic Focalin XR.

Celgene, Novartis, Elan Corporation plc (NYSE: ELN), Par Pharma and Intellipharmaceutics have settled the patent litigation concerning the 5, 10, 15 and 20 mg doses of generic version of Focalin XR. The generic companies expect the FDA to approve these generic versions by the fourth quarter of 2012.

However, in March 2011, Elan filed a patent infringement lawsuit against Par Pharma and Intellipharmaceutics, while in April, Celgene and Novartis filed a patent infringement lawsuit against the generic companies for the 30 mg strength of generic Focalin XR.

We note that Novartis has licensed the 25 mg and 35 mg strengths of Focalin XR to Elan for development and commercialization.

We currently have a Neutral recommendation for all the afore-mentioned companies – Par Pharma, Intellipharmaceutics, Celgene, Novartis and Elan.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.



RELATED LINKS

http://www.zacks.com